Invasive fungal infections following liver transplantation: Incidence, risk factors, survival, and impact of fluconazole-resistant Candida parapsilosis (2003-2007)

Liver Transplantation

Volumn 18, Issue 9, 2012, Pages 1100-1109

  Raghuram, Anupama ^a   Restrepo, Alejandro ^b   Safadjou, Saman ^c   Cooley, Jennifer ^c   Orloff, Mark ^c   Hardy, Dwight ^c   Butler, Sam ^d   Koval, Christine E ^d  

^a Department of Internal Medicine   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; CREATININE; FLUCONAZOLE; VORICONAZOLE;

ADULT; ARTICLE; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; FEMALE; FUNGAL STRAIN; FUNGUS ISOLATION; GRAFT RECIPIENT; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROBIAL COLONIZATION; MINIMUM INHIBITORY CONCENTRATION; MODEL FOR END STAGE LIVER DISEASE SCORE; MYCOSIS; NONHUMAN; POSTOPERATIVE INFECTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURGICAL MORTALITY; SURVIVAL RATE; SYSTEMIC MYCOSIS;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDA; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINNESOTA; MULTIVARIATE ANALYSIS; MYCOSES; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84865584511     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23467     Document Type: Article

References (27)

1. Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RL, Lewis WD, Karchmer AW,. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170: 644-652. (Pubitemid 24262267)
2. Briegel J, Forst H, Spill B, Haas A, Grabein B, Haller M, et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995; 14: 375-382.
3. Kusne S, Dummer JS, Singh N, Iwatsuki S, Makowka L, Esquivel C, et al. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) 1988; 67: 132-143.
4. Singh N, Gayowski T, Wagener MM, Doyle H, Marino IR,. Invasive fungal infections in liver transplant recipients receiving tacrolimus as the primary immunosuppressive agent. Clin Infect Dis 1997; 24: 179-184. (Pubitemid 27081540)
5. Husain S, Tollemar J, Dominguez EA, Baumgarten K, Humar A, Paterson DL, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003; 75: 2023-2029. (Pubitemid 36793286)
6. Nieto-Rodriguez JA, Kusne S, Mañez R, Irish W, Linden P, Magnone M, et al. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg 1996; 223: 70-76.
7. Rabkin JM, Oroloff SL, Corless CL, Benner KG, Flora KD, Rosen HR, Olyaei AJ,. Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg 2000; 179: 426-430. (Pubitemid 30621656)
8. Singh N, Arnow PM, Bonham A, Dominguez E, Paterson DL, Pankey GA, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997; 64: 716-720. (Pubitemid 27407098)
9. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al.; for Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
10. Pappas PG, Andes D, Schuster M, Hadley S, Rabkin J, Merion RM, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant 2006; 6: 386-391. (Pubitemid 43382176)
11. George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, Rubin RH,. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103: 106-113. (Pubitemid 27352114)
12. Patel R, Portela D, Badley AD, Harmsen WS, Larson-Keller JJ, Ilstrup DM, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996; 62: 926-934. (Pubitemid 26360353)
13. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P,. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006; 12: 850-858.
14. Winston DJ, Pakrasi A, Busuttil RW,. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 729-737. (Pubitemid 29531981)
15. Fortún J, Martín-Davila P, Moreno S, Barcena R, de Vicente E, Honrubia A, et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003; 52: 813-819. (Pubitemid 37407810)
16. Hadley S, Huckabee C, Pappas PG, Daly J, Rabkin J, Kauffman CA, et al. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis 2009; 11: 40-48.
17. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al.; for Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer and Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14. (Pubitemid 33152659)
18. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101-1111.
19. Singh N, Avery RK, Munoz P, Pruett TL, Alexander B, Jacobs R, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36: 46-52. (Pubitemid 36099096)
20. Pfaller MA, Diekema DJ,; for International Fungal Surveillance Participant Group. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10 (suppl 1): 11-23. (Pubitemid 38386593)
21. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al.; for Global Antifungal Surveillance Group. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366-1377.
22. Krcmery V, Barnes AJ,. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-260. (Pubitemid 37554852)
23. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ng KP, Colombo A, et al.; for Global Antifungal Surveillance Group. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK antifungal surveillance program, 2001 to 2005. J Clin Microbiol 2008; 46: 842-849. (Pubitemid 351379967)
24. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, et al.; for CLSI Subcommittee for Antifungal Testing. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14: 164-176.
25. Weems JJ Jr,. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992; 14: 756-766.
26. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-1703.
27. Verma A, Wade JJ, Cheeseman P, Samaroo B, Rela M, Heaton ND, et al. Risk factors for fungal infection in paediatric liver transplant recipients. Pediatr Transplant 2005; 9: 220-225. (Pubitemid 40476852)